PsychiatricTimes Members: Login | Register

|     

PsychiatricTimes SearchMedica Medline Drugs

Powered by SearchMedica

 
Risk Assessment
News
Current Issues
Blogs
Special Reports
CME
Conferences
Resources
Careers
Multimedia
About Us
 

Home » Blogs » Couch in Crisis

Psychiatric Times.
 

Antidepressant Use Has Gone Crazy: Bad News From the CDC

By Allen Frances, MD | October 28, 2011

A new CDC study based on a large survey of the general population reveals the following alarming results:

•Rates of antidepressant use continue to escalate- a remarkable 11% of the general population now takes an antidepressant. Antidepressants are now the third most prescribed class of medications in the US- and are first in the18 to 44 age group. Rates of antidepressant use have increased an astounding 400% in just 15 years.

•Far too often, the wrong people are on antidepressants, and the right people aren’t taking them. Just one third of severely depressed people who really need the medication are taking it, while more than two thirds on antidepressants are not currently depressed.

•Since the placebo response rate for mild depression approaches 50%, it seems obvious that many people are using antidepressants as placebos- incurring their side effects and costs without any real benefit from the active ingredient in the pill.

•Many people probably stay on antidepressants for too long. More than 60% have been taking them for more than two years and 14% for more than 10 years. Of course, people with chronic or severe depressive illness require long -term maintenance care. But the sharp escalation of antidepressant use in those with mild or nonexistent disorder suggests that much of the prolonged use is unnecessary and placebo driven.

•Antidepressants are often prescribed loosely. Fewer than one third of antidepressant users have consulted a mental health professional in the past year. Most of the prescriptions are written by primary care doctors, with little training in psychiatric diagnosis and treatment, after very brief visits and under the influence of drug salesmanship.

How did we get into this mess? There is no mystery. The massive overuse of antidepressants (and also antipsychotics) began about fifteen years ago when drug companies in the US were given a precious and unprecedented privilege- one that is appropriately denied them in the rest of the world. They were suddenly free to advertise directly to their potential customers on TV, in magazines, and on the Internet. The companies also aggressively built up their marketing to doctors, especially primary care physicians who were “educated” into the notion that depression was being frequently missed in their practices and that it is a simple “chemical imbalance” easily corrected by a pill. The consequent casual medicalization of normality mislabeled as sick many people with nothing more than the expectable symptoms of everyday life.

The results were entirely predictable. The drug companies have made huge profits peddling unneeded pills prescribed mostly by untrained primary care physicians to patients who are misled into wanting medication by a campaign of false advertising that suggests pills are necessary to deal with life problems that really aren’t depression or a chemical imbalance after all and then the placebo effect turns many into long term true believers who loyal customers for life. Giving drug companies the undeserved and much abused freedom to advertise has resulted in huge waste and misallocation of resources, to say nothing of unnecessary side effects.

What are the clear implications for the future? We need to do a much better job of getting antidepressants to the people who really need them and to reduce their wild misuse in those who really don’t. Direct to consumer advertising should be outlawed- just as it is in the rest of the world. Primary care doctors need to be re-educated and refocused toward spotting severe depression and away from their loose prescription habits. The public must be re-educated away from the notion that all of life’s inevitable sadnesses require medication and toward the realization that most of a pill’s magic for mild depression is placebo effect.

What are the implications for patients? Most important—if you are clearly and persistently depressed and are not taking medication, you should consult a mental health professional—and the sooner the better. Medicine and psychotherapy can be a big help and it makes no sense to continue suffering on your own. On the other hand, if you have been taking antidepressants for a mild depression or for a depression that is now better, this is a good time to re-evaluate whether you need to continue. But don’t do this on your own. You may run into problems of recurrence or medication withdrawal effects. So consult a mental health clinician to discuss whether medication is still necessary and if not how best to gradually discontinue it.

The prescription of antidepressants is increasingly out of control because it is being controlled by drug companies who profit from it being out of control. The pushback can come only from government regulation that better controls misleading marketing and reeducating physicians and the public to help unlearn the lessons previously taught by drug companies.

DSM-5 is a step in just the wrong direction. It is proposing several changes that will further increase inappropriate antidepressant use. These include: medicalizing grief, reducing the threshold for generalized anxiety disorder, and introducing new and highly questionable disorders for mixed anxiety/depression and binge eating. It is time to roll back, not expand, the reach of psychiatric diagnosis where it doesn’t belong and to refocus our efforts where they are really needed and can do the most good.

 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.

  • Oldest First
  • Newest First

by Robert Peers | November 15, 2011 2:44 AM EST

My patients don't have any of these problems. Most depression is the result of fatty maternal diet (the cause of anxiety--E Sullivan, 2011), compounded by fatty personal diet (which inflames the brain (B Culver, 2005). Being armed with the best anti-anxiety agent available (myo-Inositol powder, 5 gm/day), I am constantly on the lookout for anxious or depressed folks. I can easily reverse any depression, simply by advising a low fat diet. I treat all anxious cases with Inositol--a better serotonin 2A blocker than fluoxetine (C Brink, 2004). Results are rapid--better energy and vanquished food cravings within 4 days, followed by calmness and clearer thinking, at the 7-day mark. Later, fat is lost off the belly, muscle size increases, hair and nails grow faster, and better libido and immunity are noted. Inositol also activates a host of anti-ageing genes, including the master gene for mitochondrial biogenesis (PGC 1 alpha)--J Barger, 2008. The fat loss, hair and nail growth, and decreased craving for food (and alcohol, cannabis, etc.) may be due to lower cortisol levels, secondary to HPA axis de-activation ( J Levine, 2001), and also to better growth hormone secretion. M Aboukhatwa (2010) has shown that the main effect of almost all antidepressant drug classes is nerve membrane expansion; the new membrane is rich in endogenously synthesised Inositol, that apparently drives downstream antidepressant effects, involving the neurotrophic factor BDNF, and also hippocampal neurogenesis. I never use SSRIs or SNRIs--I have a far better treatment, and I suggest that psychiatry's biopsychosocial model of nervous disorders be replaced by a new neuropsychodietetic model--that includes anti-ageing (with energy included!).

by Noel fernando | November 04, 2011 3:03 PM EDT

Not only in US but other countries also notice the trend. It is also because of the expectations of the public as they are conditioned normal sadness is also depression. Also the prescribing of antidepressants is also done by non speacilsts.

This is a real worry as long term side effects are a problem.

by Ronald Pies | October 28, 2011 5:09 PM EDT

I generally agree with most of the points made by my colleague, Al Frances, as regards the prescription of antidepressants. As Dr. Frances suggests, however, the main problem is not one of wild-eyed "over-prescription"; rather, it is one of diagnostic-therapeutic "mis-match."It is also a mistake to assume that the increase in antidepressant prescribing during the last 20 years is, in all cases, a sign of bad medical practice.
Surely, some such cases do represent poor practice by inadequately-trained clinicians; but this is not necessarily the case, even when patients do not meet strict criteria for major depressive disorder (MDD).

As I note in a paper now in press (Innovations in Clinical Neuroscience):

On the one hand, it is clear from several studies that antidepressant prescriptions in the U.S. are written much more frequently in recent years, and that only a small proportion of prescriptions are written by psychiatrists. For example, Mojtabai and Olfson (42) found that the rate of antidepressant drug treatment in the U.S. increased more than four times between early 1990s and early 2000s. Of special concern-and supporting the "Yes" position-Mojtabai and Olfson (42) found that the rate of antidepressant treatment increased more in the group of less severely ill individuals than in those with more severe psychopathology.

More recently, Mojtabai and Olfson (2011) have published a study (43) showing that "Over the past two decades, the use of antidepressant medications has grown to the point that they are now the third most commonly prescribed class of medications in the United States. Much of this growth has been driven by a substantial increase in antidepressant prescriptions by nonpsychiatrist providers without an accompanying psychiatric diagnosis." Specifically, "the proportion of visits at which antidepressants were prescribed but no psychiatric diagnoses were noted increased from 59.5 percent to 72.7 percent."

These findings are certainly worrisome. On the other hand, the earlier Mojtabai and Olfson (2008) study (42) uncovered several socio-demographic disparities; e.g., racial/ethnic minorities continued to receive antidepressant treatment at a lower rate compared to non-Hispanic whites, raising concerns about undertreatment in some minority groups. This is consistent with the work of Gonzalez et al, who found that Mexican American and African American individuals meeting 12-month major depression criteria consistently and significantly had lower odds for any depression therapy and guideline-concordant therapies.(44)

Regarding the recent findings of increased antidepressant prescription by non-psychiatrists, it is important to highlight Mojtabai and Olfson's (2011) own caveat: "These results do not clearly indicate a rise in inappropriate antidepressant use…" Rather, "…they highlight the need to gain a deeper understanding of the factors driving this national trend and to develop effective policy responses." (43) These authors point to several such factors, including greater acceptance of antidepressants among the general public.(43) It is also possible that some cases of antidepressant prescription by PCPs involve patients whose clinical picture does not meet full DSM-IV criteria for major depressive disorder, but may still represent a debilitating condition; e.g., so-called "sub-threshold" depression, which is known to confer substantial distress and impairment.(45) Thus, the absence of a DSM-IV diagnosis, by itself, does not necessarily point to inappropriate treatment.

Also worrisome is a trend uncovered by Harman et al (46) : rates of adequate antidepressant treatment (e.g., using the minimum adequate daily dosage) peaked in 2002 (36.9%), and declined significantly by 2004 (31.7%) (p=.003). The authors noted that this downward trend in adequate AD prescribing preceded the black-box warnings included on antidepressant labels beginning in 2004. There is also a large body of evidence showing that depression is under-recognized and under-treated in geriatric patient samples, often with inadequate dosing of antidepressants. Low rates of adequate depression care in elderly persons with chronic illnesses have also been reported. (47)

Synthesis: The notion that antidepressants are widely over-prescribed is clearly simplistic. There are undoubtedly "pockets" of over-prescription, perhaps mainly in primary care settings; but there are also under-served subgroups of depressed patients, often treated with sub-therapeutic antidepressant doses. Furthermore, to my knowledge, there are no well-designed clinical studies showing that antidepressants are being widely or inappropriately prescribed for "ordinary grief" or uncomplicated bereavement, which, of course, would be inappropriate. (48). [Moreover, proposed changes in DSM-5 --e.g., elimination of the bereavement exclusion--are not likely to "medicalize grief" if psychiatrists carefully attend to the fundamental differences between ordinary grief and major depressive disorder. See Lamb K, Pies R, Zisook S: The Bereavement Exclusion for the diagnosis of major depression: to be or not to be? Psychiatry (Edgemont) 2010;7(7):19-25]

The overall situation could best be summed up not as a crisis of treatment overkill, but of treatment misalignment. As Mojtabai and Olfson (2011) put it:

"In general medical practice, antidepressant use appears to be becoming concentrated among people with less severe and poorly defined mental health conditions. Prescribing antidepressants without a psychiatric diagnosis is especially common in medical practices that prescribe the medications to a larger percentage of their patients. Yet paradoxically, a large proportion of patients with common mental disorders do not receive needed treatment because their primary care providers do not detect their conditions. The widening misalignment between diagnosis and treatment suggests the need for a deeper inquiry." (43)

Indeed, the fundamental reality obscured by the debate over antidepressant prescribing is, as Hector Gonzalez MD put it, that "Few Americans with depression actually get any kind of care, and even fewer get care consistent with the [best practice] standards of care." (49,50)

My own recommendation is generally to reserve antidepressant use for cases in which (a) psychotherapy has failed to produce or maintain significant improvement, either acutely or prophylactically; or (b) the clinical picture is one of, pronounced suffering and incapacity, melancholic features, or high risk of suicide. Long-term, maintenance treatment with antidepressants should be weighed carefully against the alternative of using some form of cognitive-behavioral or other type of evidence-based psychotherapy. --Ronald Pies MD

42. Mojtabai R, Olfson M. National trends in psychotherapy by office-based psychiatrists. Arch Gen Psychiatry. 2008;65:962-970

43. Mojtabai R, Olfson M : Proportion Of Antidepressants Prescribed Without A Psychiatric Diagnosis Is Growing. Health Affairs 2011; 30: 1434-1442

44. González HM, Vega WA, Williams DR, Tarraf W, West BT, Neighbors HW. Depression care in the United States: too little for too few. Arch Gen Psychiatry. 2010 Jan;67(1):37-46.

45. Lewinsohn PM, Solomon A, Seeley JR, Zeiss A. Clinical implications of "subthreshold" depressive symptoms. J Abnorm Psychol. 2000;109:345-51.

46. Harman JS, Edlund MJ, Fortney JC. Trends in antidepressant utilization from 2001 to 2004. Psychiatr Serv. 2009; 60:611-6.

47. Harman JS, Edlund MJ, Fortney JC, et al. The influence of comorbid chronic medical conditions on the adequacy of depression care for older Americans. J Am Geriatr Soc. 2005; 53:2178-83.

48. Lamb K, Pies R, Zisook S. The Bereavement Exclusion for the Diagnosis of Major Depression: To be, or not to be. Psychiatry (Edgmont);2010;7:19-25.

49. Wang SS. Studies:Mental ills are often overtreated, undertreated.
Wall Street Journal. January 5, 2010. Available at: http://online.
wsj.com/article/SB10001424052748703580904574638750777038042.html.

50. Pies R. Antidepressants work, sort of--our system of care does not. J Clin Psychopharmacol. 2010; 30:101-4.






 
TOPIC INDEX

Addiction Medicine
Alzheimer Disease
Anxiety Disorders
ADHD
Bipolar Disorder
Child & Adolescent Psychiatry
Dementia
Depression
DSM-5
Geriatric Psychiatry

 

Health Care Reform
Major Depressive
Disorder
OCD
Personality Disorders
Schizoaffective Disorder
Schizophrenia
Sleep Disorders
Somatoform Disorders
All Topics

 


 
FROM PHYSICIANS PRACTICE
Primary Care Can't Thrive Without Nurse Practitioners
Courtney H. Lyder, ND,  May 17, 2013
With a projected shortfall of primary-care physicians, it's time for alternate solutions to patient care. Nurse practitioners are one logical remedy.
VWhat Physicians Can Learn from the Allscripts EHR Lawsuit
Marisa Torrieri,  May 16, 2013
Lawsuit prompts question: What should physicians do to ensure they end up with a great EHR instead of buyer’s remorse?
Eight Ways ICD-9 Will Still Matter to Medical Practices
Brenda Edwards, CPC,  May 15, 2013
What should your medical practice do with your ICD-9-CM book after October 1, 2014? Keep it.
Seven Ways Technology Can Speed Up Patient Collections
Cheyenne Brinson,  May 15, 2013
Failing to adopt widely available billing and collections technology can cost medical practices big. Here's how to do it right.
Four Reasons Private Medical Practice is Becoming Extinct
Carol Stryker,  May 15, 2013
It’s becoming increasingly difficult for private medical practices to thrive. Here’s what’s driving the trend toward consolidation.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Developmental Psychopathology Comes of Age
  • The Moral Struggles of Practicing Psychiatrists
  • Grief and Depression: The Sages Knew the Difference
  • Update on Mental Health Benefits and Substance Use Disorder Services Under the Affordable Care Act
  • Psychiatry and the Myth of “Medicalization”
  • Grief and Depression: The Sages Knew the Difference
  • Synthetic Cathinones: Signs, Symptoms, and Treatment
  • Developmental Psychopathology Comes of Age
  • Psychiatry and the Myth of “Medicalization”
  • An Update on ADHD
  • Successful Aging: Strategies to Help Maintain and Nurture a Healthy Brain
  • Ethical and Legal Issues in Geriatric Psychiatry
  • Eco-Psychiatry: Why We Need to Keep the Environment in Mind
  • DSM-5: Where Do We Go From Here?
  • Suicidal Behavior: A Separate Diagnosis
Click here to subscribe to our newsletter
 
COMMENTS
  • Most Commented
  • Most Recent
  • Psychiatry and the Myth of “Medicalization”
  • Grief and Depression: The Sages Knew the Difference
  • Is it Time for a Treatment Manual to Complement DSM-5?
  • Diagnosis and its Discontents: The DSM Debate Continues
  • Lamotrigine for Major Depressive Disorder Is Inappropriate
  • Psychiatry and the Myth of “Medicalization”
  • Parity Laws: Powerful Weapon—or Pipe Dream?
  • The Moral Struggles of Practicing Psychiatrists
  • DSM-5 Won’t Solve the Overdiagnosis Problem—But Clinicians Can
  • NIMH vs DSM 5: No One Wins, Patients Lose
Click here to subscribe to our newsletter


 
CAREER CENTER

  •   Featured Jobs  
  •    Resources   
  • Psychiatry and Nurse Practitioner Opportunities
  • Associate Medical Director - Psychiatrist Delray Beach, Florida
  • Retiring Child Psychiatrist Seeks Replacement August 2010 or Before
  • Chairperson, Dept of Psychiatry Needed
  • FT Staff Psychiatrist - Excellent Benefits
  • BC Adult and Child Psychiatrits - PT and FT Positions Available
  • Managing Risks When Practicing in Three-Party Care Settings
  • 12 Tips for Making Your Practice Greener
  • Keys to Avoiding Malpractice: Standard of Care in Psychiatric Practice
  • Take This Job and Shove It
  • Merging Administrative and Academic Careers in Psychiatry


CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy